Cohort study on managing ovarian cancer
A Cohort Establishment Study of Total Management of Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer)
This study looks at how different treatments for ovarian cancer, including surgery and chemotherapy, affect patients' recovery, quality of life, and overall health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Sex | Female |
| Sponsor | Sichuan Cancer Hospital and Research Institute Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Chengdu) |
| Trial ID | NCT06018935 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to establish a comprehensive management approach for patients with ovarian cancer, including fallopian tube and primary peritoneal cancers. It will investigate the effects of various treatments such as surgery, chemotherapy, and maintenance therapy on patient prognosis and quality of life. Additionally, the study will analyze postoperative recovery, complications, and adverse reactions to treatments, while exploring preventive measures. The efficacy and safety of PARP inhibitors in clinical applications will also be assessed.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with ovarian cancer who are planning to receive treatment at the participating hospital.
Not a fit: Patients with other malignant tumors or cognitive impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the management and treatment outcomes for patients with ovarian cancer.
How similar studies have performed: While this study builds on existing knowledge, it focuses on a comprehensive management approach, which may provide new insights into ovarian cancer treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital; 2. Can cooperate with later follow-up. Exclusion Criteria: 1. Patients with other malignant tumors or previous history of other malignant tumors; 2. Have cognitive impairment.
Where this trial is running
Chengdu
- Sichuan Cancer Hospital — Chengdu, China (Recruiting)
Study contacts
- Study coordinator: Dengfeng Wang, Learned scholar
- Email: wonderful_96@163.com
- Phone: 15982222707
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.